<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682809</url>
  </required_header>
  <id_info>
    <org_study_id>000522017</org_study_id>
    <nct_id>NCT03682809</nct_id>
  </id_info>
  <brief_title>Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort</brief_title>
  <official_title>Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Southern College of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lindenhurst Eye Physicians &amp; Surgeons, PC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinicians commonly use artificial tears off label for treating contact lens (CL) discomfort
      and the dry eye associated with CLs because new artificial tear formulations have the
      potential to outperform the available CL rewetting drops. While off-label, McDonald et al.
      have previously shown that using a common artificial tear, Systane Ultra, before and after CL
      use is an effective means for treating daily disposable CL wears who have CL discomfort.
      Recently, a new formulation of artificial tears, Systane Complete, was released to the
      market. Systane Complete is a unique formulation that has combined elements from both Systane
      Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for
      evaporative dry eye) to create an artificial tear with an indication for aqueous deficient,
      evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the goal of
      this study is to determine in a randomized clinical trial if Systane Complete is able to
      effectively improve the symptoms of patients who have CL discomfort.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Soft contact lenses (CL) are the most common CL modality with over 140 million users world.
      Despite many improvements in CL materials and solutions, the advent of daily disposable CLs,
      and the addition of rewetting drops to improve CL comfort, research has shown that between
      21% to 64% of CL wearers permanently discontinue CL use because of eye discomfort. Contact
      Lens Discomfort (CLD) as defined by the Tear Film and Ocular Surface Society (TFOS) &quot;is a
      condition characterized by episodic or persistent adverse ocular sensations related to lens
      wear, either with or without visual disturbance, resulting from reduced compatibility between
      the CL and the eye's environment, which can lead to decreased wearing time and
      discontinuation of CL wear.&quot; TFOS further states that CLD is a multifactorial condition that
      stems from both CL (e.g., material design, fit, care system) and environmental factors
      (patient factors, medication compliance, external environmental factors, ocular environment).
      While environmental factors related to the patient such as age and sex are inherent,
      rewetting drops or artificial tears can be used to treat tear film deficiencies associated
      with CLD. The U.S. Food &amp; Drug Administration (FDA) defines rewetting/lubricating drops as
      &quot;an in-eye solution for use with CLs&quot; that contains &quot;one or more active ingredients (e.g.,
      ophthalmic demulcents) in sufficient concentration to alleviate symptoms of discomfort from
      CL wear by physical means.&quot; Clinicians also commonly use artificial tears off label for
      treating CLD and the dry eye associated with CLs because artificial tear formulations have
      the potential to outperform CL rewetting drops. The FDA separately classifies artificial
      tears as topical drops that contain specific types of demulcents or emollients. While
      off-label, McDonald et al. have previously shown that using a common artificial tear, Systane
      Ultra, before and after CL use is an effective means for treating daily disposable CL wears
      who have CLD. Recently, a new formulation of artificial tears, Systane Complete, was released
      to the market. Systane Complete is a unique formulation that has combined elements from both
      Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for
      evaporative dry eye) to create an artificial tear with an indication for aqueous deficient,
      evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the Research
      Goal of this study is to determine in a randomized clinical trial if Systane Complete is able
      to effectively improve the symptoms of CLD suffers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">March 23, 2019</completion_date>
  <primary_completion_date type="Actual">March 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>One group will be randomized Systane Complete, and one group will be randomized to no treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The patients who are randomized to Systane Complete will be masked to the brand of the artificial tears.
There will be a masked examiner who does not know the subject's study group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Contact Lens Symptoms</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of Day Eye Comfort</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Staining</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer's I Test Without Anesthetic</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Break-Up Time (TBUT)</measure>
    <time_frame>Baseline through 2 Weeks</time_frame>
    <description>Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Contact Lens Discomfort</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Systane Complete</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to this group will not receive a treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Complete</intervention_name>
    <description>Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
    <arm_group_label>Systane Complete</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-reported contact lens discomfort

          -  Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12

          -  Daily disposable contact lens wearer

          -  Best-corrected visual acuity of 20/30 or better

        Exclusion Criteria:

          -  All other contact lens types (e.g., currently wearing two week or monthly replacement
             contact lenses or hard contact lenses)

          -  Non-compliant daily disposable contact lens wearers (must regularly replace contact
             lenses daily)

          -  Systemic health conditions known to alter tear film physiology

          -  History of ocular surgery within the past 12 months

          -  History of severe ocular trauma, active ocular infection, or inflammation

          -  Currently using Accutane or eye medications

          -  Pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindenhurst Eye Physicians &amp; Surgeons, P.C.</name>
      <address>
        <city>Babylon</city>
        <state>New York</state>
        <zip>11702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern College of Optometry</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McDonald M, Schachet JL, Lievens CW, Kern JR. Systane® ultra lubricant eye drops for treatment of contact lens-related dryness. Eye Contact Lens. 2014 Mar;40(2):106-10. doi: 10.1097/ICL.0000000000000018.</citation>
    <PMID>24552755</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 21, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <results_first_submitted>March 23, 2020</results_first_submitted>
  <results_first_submitted_qc>March 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2020</results_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Andrew Pucker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Artificial Tears</keyword>
  <keyword>Systane Complete</keyword>
  <keyword>Contact Lens Discomfort</keyword>
  <keyword>Dry Eye</keyword>
  <keyword>Daily Disposable Contact Lenses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual subject's data. Data will only be published in aggregate form.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 4, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03682809/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Systane Complete</title>
          <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Subjects randomized to this group will not receive a treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who were 18 years an older who had a significant contact lens and dry eye questionnaire (cldeq-8) scores (12 or greater) were allowed to participate in this study. Subjects were also required to be daily disposable contact lens wearers and have a generally healthy ocular health history .</population>
      <group_list>
        <group group_id="B1">
          <title>Systane Complete</title>
          <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Subjects randomized to this group will not receive a treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.7" lower_limit="20" upper_limit="56"/>
                    <measurement group_id="B2" value="28.8" lower_limit="18" upper_limit="69"/>
                    <measurement group_id="B3" value="30.75" lower_limit="18" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Contact Lens Symptoms</title>
        <description>Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.</description>
        <time_frame>Baseline through 2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Complete</title>
            <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects randomized to this group will not receive a treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens Symptoms</title>
          <description>Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.</description>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline cldeq-8 (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.41" spread="5.40"/>
                    <measurement group_id="O2" value="18.92" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 week cldeq-8 (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.86" spread="6.40"/>
                    <measurement group_id="O2" value="17.92" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline cldeq-4 (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.91" spread="3.28"/>
                    <measurement group_id="O2" value="10.38" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 week cldeq-4 (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.14" spread="3.50"/>
                    <measurement group_id="O2" value="10.13" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End of Day Eye Comfort</title>
        <description>Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.</description>
        <time_frame>Baseline through 2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Complete</title>
            <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects randomized to this group will not receive a treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>End of Day Eye Comfort</title>
          <description>Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Speed Score Baseline (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.27" spread="3.60"/>
                    <measurement group_id="O2" value="9.67" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speed Score 2 weeks (worse eye)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.55" spread="4.31"/>
                    <measurement group_id="O2" value="9.29" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Staining</title>
        <description>Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.</description>
        <time_frame>Baseline through 2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Complete</title>
            <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects randomized to this group will not receive a treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Staining</title>
          <description>Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Corneal Staining Extent (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="2.45"/>
                    <measurement group_id="O2" value="1.63" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining Depth (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.54"/>
                    <measurement group_id="O2" value="0.92" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining Type (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="1.56"/>
                    <measurement group_id="O2" value="0.92" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining Extent (2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="2.42"/>
                    <measurement group_id="O2" value="1.75" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining Depth (2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.38"/>
                    <measurement group_id="O2" value="1.04" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining Type (2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="1.36"/>
                    <measurement group_id="O2" value="0.92" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Schirmer's I Test Without Anesthetic</title>
        <description>Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.</description>
        <time_frame>Baseline through 2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Complete</title>
            <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects randomized to this group will not receive a treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Schirmer's I Test Without Anesthetic</title>
          <description>Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Schirmers Strip Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.68" spread="9.70"/>
                    <measurement group_id="O2" value="20.88" spread="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schirmers Strip (2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.41" spread="9.29"/>
                    <measurement group_id="O2" value="18.30" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Break-Up Time (TBUT)</title>
        <description>Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.</description>
        <time_frame>Baseline through 2 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Systane Complete</title>
            <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects randomized to this group will not receive a treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Break-Up Time (TBUT)</title>
          <description>Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tear Break Up Time (seconds) (baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.70" spread="5.20"/>
                    <measurement group_id="O2" value="8.50" spread="5.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tear Break Up Time (seconds) (2 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57" spread="4.73"/>
                    <measurement group_id="O2" value="8.80" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data was collected 14-17 days after the baseline visit.</time_frame>
      <desc>There were no adverse events in this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Systane Complete</title>
          <description>Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Systane Complete: Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Subjects randomized to this group will not receive a treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The results presented in this record have no known limitations or caveats.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Andrew Pucker</name_or_title>
      <organization>The University of Alabama at Birmingham</organization>
      <phone>920-579-2900</phone>
      <email>apucker@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

